CVA Family Office LLC Buys New Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

CVA Family Office LLC bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 195 shares of the company’s stock, valued at approximately $108,000.

A number of other large investors also recently made changes to their positions in the business. Moneta Group Investment Advisors LLC lifted its stake in shares of IDEXX Laboratories by 121,647.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock worth $3,038,192,000 after purchasing an additional 7,441,162 shares during the period. State Street Corp lifted its stake in shares of IDEXX Laboratories by 2.6% during the 2nd quarter. State Street Corp now owns 3,771,574 shares of the company’s stock worth $1,894,198,000 after purchasing an additional 97,303 shares during the period. Alliancebernstein L.P. lifted its stake in shares of IDEXX Laboratories by 6.4% during the 2nd quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock worth $1,804,428,000 after purchasing an additional 214,529 shares during the period. Geode Capital Management LLC lifted its stake in shares of IDEXX Laboratories by 1.4% during the 1st quarter. Geode Capital Management LLC now owns 1,946,339 shares of the company’s stock worth $971,569,000 after purchasing an additional 26,197 shares during the period. Finally, Blair William & Co. IL lifted its stake in shares of IDEXX Laboratories by 0.7% during the 3rd quarter. Blair William & Co. IL now owns 1,199,945 shares of the company’s stock worth $524,700,000 after purchasing an additional 7,812 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the transaction, the senior vice president now owns 6,712 shares in the company, valued at $3,851,815.44. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of IDEXX Laboratories stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the transaction, the chief executive officer now owns 79,247 shares of the company’s stock, valued at approximately $45,377,624.67. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares in the company, valued at approximately $3,851,815.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,524 shares of company stock worth $24,871,960. 2.11% of the stock is owned by insiders.

Analyst Ratings Changes

IDXX has been the topic of a number of recent analyst reports. BNP Paribas assumed coverage on IDEXX Laboratories in a research note on Thursday, December 7th. They set an “outperform” rating and a $602.00 price target on the stock. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a report on Friday, January 5th. JPMorgan Chase & Co. upped their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Barclays upped their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Finally, Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a report on Tuesday, January 30th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $591.50.

Get Our Latest Stock Analysis on IDXX

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $529.71 on Tuesday. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17. The firm has a market capitalization of $44.01 billion, a PE ratio of 52.60, a P/E/G ratio of 2.91 and a beta of 1.27. The company’s 50 day simple moving average is $547.66 and its 200 day simple moving average is $500.88.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last posted its quarterly earnings data on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The business had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. During the same quarter last year, the business earned $2.05 earnings per share. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.15 EPS for the current fiscal year.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

See Also

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.